Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...
Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
The Motley Fool on MSN12d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its HandsIn fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
Yahoo Finance on MSN9d
Novo Nordisk 'comfortable' with impact of Medicare price negotiations for GLP-1s: CEONovo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...
LONDON/COPENHAGEN (Reuters) -Novo Nordisk defended its next-generation ... Lilly emerges as a strong competitor in the biggest market for obesity drugs, the United States. Novo plans to begin ...
the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was 20.2%, while Wegovy's was 13.7%. Amycretin did better in half the time. Novo Nordisk faces at least two ...
The two drugs have helped turn Novo Nordisk into Europe's biggest firm by market capitalisation and driven a considerable amount of Denmark's economic success. The Danish economy ministry cited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback